5-(1,3-benzodioxol-5-yl)-N-(2,4-dimethoxybenzyl)-1-methyl-1H-imidazol-2-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(1,3-benzodioxol-5-yl)-N-(2,4-dimethoxybenzyl)-1-methyl-1H-imidazol-2-amine
• 英文别名: 5-(1,3-benzodioxol-5-yl)-N-[(2,4-dimethoxyphenyl)methyl]-1-methylimidazol-2-amine
• 化学式: C₂₀H₂₁N₃O₄
• 分子量: 367.4
• InChiKey: AKQCUNWVVQYIIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• NOVEL SMALL MOLECULE COMPOUND INHIBITING SIGNAL TRANSMISSION PATH OF TLR7 AND TLR9 AND USE THEREOF
  申请人：Ajou University Industry-Academic Cooperation Foundation

  公开号：EP4006013A1

  公开（公告）日：2022-06-01

  The present invention relates to a small molecule compound inhibiting a toll-like receptor (TLR) signal transmission path and, more specifically, to a compound having a structure expressed by a particular chemical formula, a TLR inhibitory composition comprising same, and an autoimmune disease or inflammatory disease prevention or therapeutic composition comprising the TLR inhibitory composition. In the present invention, a TLR inhibitory compound TIC10, inhibiting a TLR7- and TLR9-mediated signal transmission path, and a derivative TIC10-7 thereof have been confirmed. The novel compounds block the TNF-α secretion by inhibiting the expression and activation of NF-κB- and MAPK-related proinflammatory genes, and thus can be utilized as a therapeutic agent for many autoimmune diseases, such as systemic lupus erythematosus, psoriasis and psoriatic arthritis, associated with a hyperactivity of a nucleic acid detection TLR.

  本发明涉及一种抑制收费样受体（TLR）信号传导途径的小分子化合物，更具体地说，涉及一种具有由特定化学式表示的结构的化合物、包含该化合物的TLR抑制性组合物以及包含该TLR抑制性组合物的自身免疫性疾病或炎症性疾病预防或治疗组合物。在本发明中，一种抑制 TLR7 和 TLR9 介导的信号传输路径的 TLR 抑制性化合物 TIC10 及其衍生物 TIC10-7 已被证实。这些新型化合物通过抑制 NF-κB 和 MAPK 相关促炎基因的表达和活化来阻断 TNF-α 的分泌，因此可用作与核酸检测 TLR 活性亢进相关的许多自身免疫性疾病（如系统性红斑狼疮、银屑病和银屑病关节炎）的治疗剂。